TCGA-60-2698-01A-01R-0851-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 62
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.470
- INTERFERON_ALPHA_RESPONSE+0.460
- IL6_JAK_STAT3_SIGNALING+0.450
- INFLAMMATORY_RESPONSE+0.420
- INTERFERON_GAMMA_RESPONSE+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- MTORC1_SIGNALING+0.380
- CHOLESTEROL_HOMEOSTASIS+0.350
- COMPLEMENT+0.350
- ALLOGRAFT_REJECTION+0.340
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.240
- PANCREAS_BETA_CELLS-0.200
- UV_RESPONSE_DN-0.120
- APICAL_SURFACE-0.080
- HEDGEHOG_SIGNALING-0.030
- NOTCH_SIGNALING-0.020
- PROTEIN_SECRETION-0.010
- MYOGENESIS+0.010
- BILE_ACID_METABOLISM+0.050
- MITOTIC_SPINDLE+0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_X59HSFGG | low-grade glioma | — | 0.888 |
| 2 | SRR8942975 | — | — | 0.884 |
| 3 | MDT-AP-2036 | Med | Medulloblastoma | 0.872 |
| 4 | SRR6013499 | — | cohortA1 | 0.866 |
| 5 | BS_GJNCYABP | ATRT | — | 0.864 |
| 6 | SRR6013500 | — | cohortA1 | 0.862 |
| 7 | A0396799-AB5C-401F-81FF-7C829A3CF1E4 | — | — | 0.858 |
| 8 | TCGA-K4-A54R-01A-11R-A26T-07 | — | — | 0.856 |
| 9 | DRR168600 | — | — | 0.856 |
| 10 | SRR8942992 | — | — | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.350 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.220 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |